Diabetes Drugs Are Sound, BMS Insists
This article was originally published in The Pink Sheet Daily
Executive Summary
In post-ADA briefing, execs downplay side effects.
You may also be interested in...
Bristol-Myers Squibb Targets Mid-year Filing For Saxagliptin
Bristol and AstraZeneca reveal Onglyza brand name, positive monotherapy data for the DPP-4 inhibitor at American Diabetes Association meeting.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.